Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
10.3350/cmh.2014.20.2.218
- Author:
Joon Il CHOI
1
;
David K IMAGAWA
;
Priya BHOSALE
;
Puneet BHARGAVA
;
Temel TIRKES
;
Tara E SEERY
;
Chandana LALL
Author Information
1. Department of Radiology, Seoul St. Mary's Hospital, College of Medicine The Catholic University of Korea, Seoul, Korea.
- Publication Type:Case Reports ; Research Support, Non-U.S. Gov't ; Review
- Keywords:
Hepatocellular carcinoma;
MRI;
Sorafenib;
mRECIST
- MeSH:
Aged;
Antineoplastic Agents/*therapeutic use;
Carcinoma, Hepatocellular/drug therapy/physiopathology/*radiography;
Female;
Humans;
Liver Neoplasms/drug therapy/physiopathology/*radiography;
*Magnetic Resonance Imaging;
Male;
Middle Aged;
Niacinamide/*analogs & derivatives/therapeutic use;
Phenylurea Compounds/*therapeutic use;
Tomography, X-Ray Computed
- From:Clinical and Molecular Hepatology
2014;20(2):218-222
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hepatocellular carcinomas are highly vascular tumors, showing progressive hypervascularity by the process of neoangiogenesis. Tumor angiogenesis is critical for tumor growth as well as metastatic spread therefore, imaging and quantification of tumor neo-angiogenesis is essential for monitoring response to targeted therapies and predicting disease progression. Sorafenib is a molecular targeting agent used for treating hypervascular tumors. This drug is now the standard of care in treatment of patients with advanced hepatocellular carcinoma. Due to its anti-angiogenic and anti-proliferative actions, imaging findings following treatment with Sorafenib are quite distinct when compared to conventional chemotherapeutic agents. Liver MRI is a widely adopted imaging modality for assessing treatment response in hepatocellular carcinoma and imaging features may reflect pathophysiological changes within the tumor. In this mini-review, we will discuss MRI findings after Sorafenib treatment in hepatocellular carcinoma and review the feasibility of MRI as an early biomarker in differentiating responders from non-responders after treatment with molecular targeting agents.
